Catalyst
Slingshot members are tracking this event:
Rigel (RIGL) Plans to Submit a New Drug Application for Fostamatinib in Immune Thrombocytopenic Purpura (ITP) in Q1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
RIGL |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 17, 2017
Occurred Source:
http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=2262310
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fit Program, Chronic Itp, Blood Platelet Count, Immune Thrombocytopenic Purpura, Itp